COMMUNIQUÉS West-GlobeNewswire

Dark Horse Consulting Group Marks the Opening of Its Shanghai Office with Ribbon Cutting Ceremony
09/09/2026
WALNUT CREEK, Calif. and SHANGHAI, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (DHCG) marked the opening of its Shanghai office with a ribbon cutting ceremony celebrating Dark Horse Consulting China. [...]
Zoher F. Kapasi, PhD, PT, Named Provost of Thomas Jefferson University
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Thomas Jefferson University has announced the appointment of Zoher F. Kapasi, PhD, PT, as its next Provost effective Nov. 1, 2026. With extensive experience in higher [...]
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
09/09/2026
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the [...]
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
09/09/2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in [...]
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
09/09/2026
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/09/2026
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Century Therapeutics Appoints Joseph Truitt to Board of Directors
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
09/09/2026
Board Unanimously Concludes to Retain CooperSurgical Expands Share Repurchase Authorization from $2 billion to $3 billion Board Remains Open to All Value Options that Create Shareholder Value SAN RAMON, Calif., Sept. 09 [...]
NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
09/09/2026
PARIS and CAMBRIDGE, Mass., 09 sept. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
Crescent Biopharma Announces Grants of Inducement Awards
09/09/2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
CooperCompanies Announces Third Quarter 2026 Results
09/09/2026
SAN RAMON, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2026. Revenue [...]
Venus Concept Announces CEO Transition
09/09/2026
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer [...]
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for [...]
AdCare Hospital Expands Detox Services with New 12-Bed Unit, Helping More People Access Care in Worcester
09/09/2026
WORCESTER, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- For decades, AdCare Hospital has been a staple in the Worcester community, providing hospital-level detox services for people struggling with substance use disorders [...]
Quetzal Therapeutics Appoints Harindra R. Abeysinghe, Ph.D., as Chief Regulatory and Quality Officer
09/09/2026
CHICAGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare diseases, including hematologic malignancies, today announced the appointment of [...]
Fast Company Names Visory Health to Its 2026 Best Workplaces for Innovators List
09/09/2026
The company’s collaborative culture and commitment to empowering employees earned the prestigious recognition ESTERO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Visory Health , a top-three prescription discount card [...]
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
09/09/2026
Nantes, le 9 septembre 2026 – 18h00 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo : OSE) (la « Société ») se félicite de l’annonce de son partenaire Veloxis Pharmaceuticals, Inc. relative au traitement [...]

Pages